{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:58:43Z","timestamp":1775743123591,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00482-020-00503-8","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:03:01Z","timestamp":1601042581000},"page":"114-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nicht-indikationsgem\u00e4\u00dfer Einsatz schnell freisetzender Fentanylzubereitungen","Use of rapid-onset fentanyl preparations beyond indication"],"prefix":"10.1007","volume":"35","author":[{"given":"Stefan","family":"Wirz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christian","family":"Wartenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Cascella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Kieselbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"2","key":"503_CR1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s13181-016-0535-y","volume":"12","author":"American College of Medical Toxicology","year":"2016","unstructured":"American College of Medical Toxicology (2016) ACMT position statement: safety issues regarding prescription fentanyl products. J\u00a0Med Toxicol 12(2):211\u2013212","journal-title":"J Med Toxicol"},{"key":"503_CR2","unstructured":"Arzneimittelgesetz \u00a7 11 AMG \u2013 Packungsbeilage, \u00a7 11a AMG \u2013 Fachinformation"},{"key":"503_CR3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00000542-198910000-00026","volume":"71","author":"MA Ashburn","year":"1989","unstructured":"Ashburn\u00a0MA, Fine\u00a0PG, Stanley\u00a0TH (1989) Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: a\u00a0case report. Anesthesiology 71:615","journal-title":"Anesthesiology"},{"key":"503_CR4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1213\/ANE.0b013e318209d320","volume":"112","author":"MA Ashburn","year":"2011","unstructured":"Ashburn\u00a0MA, Slevin\u00a0KA, Messina\u00a0J et al (2011) The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg 112:693\u2013702","journal-title":"Anesth Analg"},{"key":"503_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pain.2007.03.028","volume":"129","author":"JC Ballantyne","year":"2007","unstructured":"Ballantyne\u00a0JC, LaForge\u00a0KS (2007) Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129:235\u2013255","journal-title":"Pain"},{"key":"503_CR6","unstructured":"Bf AR (2019) https:\/\/www.bfarm.de\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/Schulungsmaterial\/Wirkstoff\/_node_Wirkstoff.html. Zugegriffen: 14. Jan. 2019"},{"key":"503_CR7","first-page":"354","volume":"30","author":"D Bennett","year":"2005","unstructured":"Bennett\u00a0D, Burton\u00a0AW, Fishman\u00a0S (2005) Consensus panel recommendations for the assessment and management of breakthrough pain. Part II-management. Pharm Ther 30:354\u2013361","journal-title":"Pharm Ther"},{"key":"503_CR8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/annonc\/mdp001","volume":"20","author":"H Breivik","year":"2009","unstructured":"Breivik\u00a0H, Cherny\u00a0N, Collett\u00a0B et al (2009) Cancer-related pain: a\u00a0pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20:1420\u20131433","journal-title":"Ann Oncol"},{"key":"503_CR9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jpain.2010.02.019","volume":"11","author":"CR Chapman","year":"2010","unstructured":"Chapman\u00a0CR, Lipschitz\u00a0DL, Angst\u00a0MS et al (2010) Opioid pharmacotherapy for chronic non-cancer pain in the United States: a\u00a0research guideline for developing an evidence-base. J\u00a0Pain 11:807\u2013829","journal-title":"J Pain"},{"issue":"2","key":"503_CR10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5055\/jom.2008.0016","volume":"4","author":"F Collado","year":"2008","unstructured":"Collado\u00a0F, Torres\u00a0LM (2008) Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naive patients with severe chronic noncancer pain. J\u00a0Opioid Manag 4(2):111\u2013115","journal-title":"J Opioid Manag"},{"issue":"8","key":"503_CR11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/ern.11.63","volume":"11","author":"MP Davis","year":"2011","unstructured":"Davis\u00a0MP (2011) Fentanyl for breakthrough pain: a\u00a0systematic review. Expert Rev Neurother 11(8):1197\u20131216","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"503_CR12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/bja\/aep253","volume":"103","author":"J Devulder","year":"2009","unstructured":"Devulder\u00a0J, Jacobs\u00a0A, Richarz\u00a0U et al (2009) Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain. Br J Anaesth 103(4):576\u2013585","journal-title":"Br J Anaesth"},{"issue":"3","key":"503_CR13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00101-014-2413-9","volume":"64","author":"J Erlenwein","year":"2015","unstructured":"Erlenwein\u00a0J, Emons\u00a0M, Hecke\u00a0A et\u00a0al (2015) Behandlungsstandards in der postoperativen Akutschmerztherapie Analyse von Inhalten standardisierter medikament\u00f6ser Konzepte. Anaesthesist 64(3):218\u2013226","journal-title":"Anaesthesist"},{"key":"503_CR14","unstructured":"Fachinformation Actiq Fa. Teva, Ulm, Version Ulm, Stand Mai 2019"},{"key":"503_CR15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1526-4637.2010.00939.x","volume":"11","author":"JT Farrar","year":"2010","unstructured":"Farrar\u00a0JT, Messina\u00a0J, Xie\u00a0F et al (2010) A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med 11:1313\u20131327","journal-title":"Pain Med"},{"key":"503_CR16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jpainsymman.2010.02.009","volume":"40","author":"PG Fine","year":"2010","unstructured":"Fine\u00a0PG, Messina\u00a0J, Xie\u00a0F et al (2010) Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J\u00a0Pain Symptom Manage 40:747\u2013760","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"503_CR17","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1526-4637.2010.00891.x","volume":"11","author":"PG Fine","year":"2010","unstructured":"Fine\u00a0PG, Narayana\u00a0A, Passik\u00a0SD (2010) Treatment of breakthrough pain with Fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. Pain Med 11(7):1024\u20131036","journal-title":"Pain Med"},{"key":"503_CR18","unstructured":"Food and Drug Administration (2012) Transmucosal immediate release fentanyl (TIRF) risk evaluation and mitigation strategy (REMS). http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM289730.pdf. Zugegriffen: 17.9.2020"},{"issue":"5","key":"503_CR19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/pme.12382","volume":"15","author":"R Granata","year":"2014","unstructured":"Granata\u00a0R, Bossi\u00a0P, Bertulli\u00a0R et al (2014) Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. Pain Med 15(5):758\u2013761","journal-title":"Pain Med"},{"issue":"46","key":"503_CR20","first-page":"785","volume":"114","author":"D H\u00e4ske","year":"2017","unstructured":"H\u00e4ske\u00a0D, B\u00f6ttiger\u00a0BW, Bouillon\u00a0B et\u00a0al (2017) Analgesia in Patients with Trauma in Emergency Medicine. Dtsch Arztebl Int 114(46):785\u2013792","journal-title":"Dtsch Arztebl Int"},{"key":"503_CR21","doi-asserted-by":"crossref","unstructured":"H\u00e4user W (2020) 2. Aktualisierung der S3 Leitlinie \u201eLangzeitanwendungen von Opioiden bei chronischen nicht-tumorbedingten Schmerzen \u201eLONTS\u201c. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/145-003l_S3_LONTS_2020-04.pdf. Zugegriffen:  17.9.2020","DOI":"10.1007\/s00482-020-00471-z"},{"issue":"4","key":"503_CR22","doi-asserted-by":"crossref","first-page":"e202875","DOI":"10.1001\/jamanetworkopen.2020.2875","volume":"3","author":"MM Jeffery","year":"2020","unstructured":"Jeffery\u00a0MM, Chaisson\u00a0CE, Hane\u00a0C, Rumanes\u00a0L, Tucker\u00a0J, Hang\u00a0L, McCoy\u00a0R, Chen\u00a0CL, Bicket\u00a0MC, Hooten\u00a0WM, Larochelle\u00a0M, Becker\u00a0WC, Kornegay\u00a0C, Racoosin\u00a0JA, Sanghavi\u00a0D (2020) Assessment of potentially inappropriate prescribing of opioid analgesics requiring prior opioid tolerance. JAMA Netw Open 3(4):e202875","journal-title":"JAMA Netw Open"},{"key":"503_CR23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1553-2712.2010.00905.x","volume":"17","author":"AP Karlsen","year":"2010","unstructured":"Karlsen\u00a0AP, Pedersen\u00a0DM, Trautner\u00a0S et\u00a0al (2010) Use of intranasal fentanyl for the relief of pediatric orthopedic trauma pain. Acad Emerg Med 17:1155\u20131161","journal-title":"Acad Emerg Med"},{"issue":"7","key":"503_CR24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.ajem.2017.11.015","volume":"36","author":"GS Kelly","year":"2018","unstructured":"Kelly\u00a0GS, Stewart\u00a0RW, Strouse\u00a0JJ, Anders\u00a0JF (2018) Intranasal fentanyl improves time to analgesic delivery in sickle cell pain crises. Am J Emerg Med 36(7):1305\u20131307","journal-title":"Am J Emerg Med"},{"issue":"8","key":"503_CR25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1526-4610.2004.04142.x","volume":"44","author":"SH Landy","year":"2004","unstructured":"Landy\u00a0SH (2004) Oral transmucosal fentanyl citrate for the treatment of migraine headache\u00a0pain\u00a0in outpatients: a\u00a0case series. Headache 44(8):762\u2013766","journal-title":"Headache"},{"issue":"3","key":"503_CR26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pain.2008.03.011","volume":"136","author":"JD Markman","year":"2008","unstructured":"Markman\u00a0JD (2008) Not so fast: the reformulation of fentanyl\u00a0and breakthrough chronic non-cancer pain. Pain 136(3):227\u2013229","journal-title":"Pain"},{"key":"503_CR27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7326\/0003-4819-146-2-200701160-00006","volume":"146","author":"BA Martell","year":"2007","unstructured":"Martell\u00a0BA, O\u2019Connor\u00a0PG, Kerns\u00a0RD et\u00a0al (2007) Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 146:116\u2013127","journal-title":"Ann Intern Med"},{"key":"503_CR28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.10249","volume":"94","author":"SM Mercadante","year":"2002","unstructured":"Mercadante\u00a0SM, Radbruch\u00a0L, Caraceni et\u00a0al (2002) Episodic (breakthrough) pain. Consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94:832\u2013839","journal-title":"Cancer"},{"issue":"6","key":"503_CR29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/MEJ.0000000000000389","volume":"24","author":"AP Murphy","year":"2017","unstructured":"Murphy\u00a0AP, Hughes\u00a0M, Mccoy\u00a0S, Crispino\u00a0G, Wakai\u00a0A, O\u2019Sullivan\u00a0R (2017) Intranasal fentanyl for the prehospital management of acute pain in children. Eur J Emerg Med 24(6):450\u2013454","journal-title":"Eur J Emerg Med"},{"issue":"4","key":"503_CR30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1185\/03007995.2011.554808","volume":"27","author":"SR Nalamachu","year":"2011","unstructured":"Nalamachu\u00a0SR, Narayana\u00a0A, Janka\u00a0L (2011) Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Curr Med Res Opin 27(4):751\u2013760","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"503_CR31","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2011.07.006","volume":"42","author":"JM Nu\u00f1ez-Olarte","year":"2011","unstructured":"Nu\u00f1ez-Olarte\u00a0JM, Alvarez-Jim\u00e9nez\u00a0P (2011) Emerging opioid abuse in terminal cancer patients oral transmucosal fentanyl citrate for breakthrough pain. J\u00a0Pain Symptom Manage 42(6):e6\u2013e8","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"503_CR32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1526-4637.2008.00413.x","volume":"9","author":"AB O\u2019Connor","year":"2008","unstructured":"O\u2019Connor\u00a0AB (2008) Is\u00a0actiq\u00a0use in\u00a0noncancer-related\u00a0pain\u00a0really \u201ca\u00a0recipe\u00a0for\u00a0success\u201d? Pain Med 9(2):258\u2013260","journal-title":"Pain Med"},{"issue":"1","key":"503_CR33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.medipa.2011.12.002","volume":"20","author":"PA Jim\u00e9nez","year":"2013","unstructured":"Jim\u00e9nez\u00a0PA, P\u00e9rez\u00a0AQ, N\u00fa\u00f1ez Olarte\u00a0JM (2013) Conductas aberrantes asociadas al empleo de fentanilos r\u00e1pidos en pacientes oncol\u00f3gicos terminales: a\u00a0prop\u00f3sito de un caso. Med Paliat 20(1):26\u201331","journal-title":"Med Paliat"},{"issue":"3","key":"503_CR34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00482-010-0913-3","volume":"24","author":"M Pflughaupt","year":"2010","unstructured":"Pflughaupt\u00a0M, Scharnagel\u00a0R, Gossrau\u00a0G et\u00a0al (2010) Befragung schmerztherapeutisch interessierter \u00c4rzte zum Umgang mit Opioiden. Schmerz 24(3):267\u2013275","journal-title":"Schmerz"},{"key":"503_CR35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jpain.2006.02.003","volume":"7","author":"RK Portenoy","year":"2006","unstructured":"Portenoy\u00a0RK, Bennett\u00a0DS, Rauck\u00a0R et al (2006) Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J\u00a0Pain 7:583\u2013591","journal-title":"J Pain"},{"key":"503_CR36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","volume":"41","author":"RK Portenoy","year":"1990","unstructured":"Portenoy\u00a0RK, Hagen\u00a0NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273","journal-title":"Pain"},{"key":"503_CR37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/030079906X162818","volume":"23","author":"RK Portenoy","year":"2007","unstructured":"Portenoy\u00a0RK, Messina\u00a0J, Xie\u00a0F et al (2007) Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a\u00a0randomized, placebo-controlled study. Curr Med Res Opin 23:223\u2013233","journal-title":"Curr Med Res Opin"},{"key":"503_CR38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3959(99)00006-8","volume":"81","author":"RK Portenoy","year":"1999","unstructured":"Portenoy\u00a0RK, Payne\u00a0D, Jacobsen\u00a0P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129\u2013134","journal-title":"Pain"},{"key":"503_CR39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ajem.2007.02.027","volume":"25","author":"C Rickard","year":"2007","unstructured":"Rickard\u00a0C, O\u2019Meara\u00a0P, McGrail\u00a0M et\u00a0al (2007) A randomized controlled trial of intranasal fentanyl vs intravenous morphine for analgesia in the prehospital setting. Am J Emerg Med 25:911\u2013917","journal-title":"Am J Emerg Med"},{"issue":"7","key":"503_CR40","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.2019.0235","volume":"321","author":"JE Rollman","year":"2019","unstructured":"Rollman\u00a0JE, Heyward\u00a0J, Olson\u00a0L, Lurie\u00a0P, Sharfstein\u00a0J, Alexander\u00a0GC (2019) Assessment of the FDA risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl products. JAMA 321(7):676\u2013685","journal-title":"JAMA"},{"key":"503_CR41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00482-012-1278-6","volume":"27","author":"R Scharnagel","year":"2013","unstructured":"Scharnagel\u00a0R, Kaiser\u00a0U, Sch\u00fctze\u00a0A et\u00a0al (2013) Chronische nichttumorbedingte Schmerzen Langzeitbehandlung mit schnell freisetzenden und kurz wirksamen Opioiden im Kontext von Missbrauch und Abh\u00e4ngigkeit. Schmerz 27:7\u201319","journal-title":"Schmerz"},{"key":"503_CR42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.clinthera.2007.04.007","volume":"29","author":"DM Simpson","year":"2007","unstructured":"Simpson\u00a0DM, Messina\u00a0J, Xie\u00a0F et al (2007) Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a\u00a0multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 29:588\u2013560","journal-title":"Clin Ther"},{"issue":"2","key":"503_CR43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5055\/jom.2011.0053","volume":"7","author":"KA Slevin","year":"2011","unstructured":"Slevin\u00a0KA, Ashburn\u00a0MA (2011) Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J\u00a0Opioid Manag 7(2):109\u2013115","journal-title":"J Opioid Manag"},{"issue":"1","key":"503_CR44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpainsymman.2010.03.012","volume":"41","author":"SD Passik","year":"2010","unstructured":"Passik\u00a0SD, Messina\u00a0JC, Golsorkhi\u00a0A et al (2010) Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl Buccal tablet for breakthrough pain. J\u00a0Pain Symptom Manage 41(1):116","journal-title":"J Pain Symptom Manage"},{"key":"503_CR45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00000542-199208000-00010","volume":"77","author":"HW Striebel","year":"1992","unstructured":"Striebel\u00a0HW, Koenigs\u00a0D, Krfimer\u00a0J (1992) Postoperative pain management by intranasal demand-adapted fentanyl titration. Anesthesiology 77:281","journal-title":"Anesthesiology"},{"key":"503_CR46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejpain.2004.06.001","volume":"9","author":"KB Svendsen","year":"2005","unstructured":"Svendsen\u00a0KB, Andersen\u00a0S, Arnason\u00a0S et al (2005) Breakthrough pain in malignant and non-malignant diseases: a\u00a0review of prevalence, characteristics and mechanisms. Eur J Pain 9:195\u2013206","journal-title":"Eur J Pain"},{"key":"503_CR47","first-page":"1","volume":"23","author":"A Tanguay","year":"2020","unstructured":"Tanguay\u00a0A, Lebon\u00a0J, H\u00e9bert\u00a0D, B\u00e9gin\u00a0F (2020) Intranasal fentanyl versus subcutaneous fentanyl for pain management in prehospital patients with acute pain: a retrospective analysis. Prehosp Emerg Care 23:1\u20139","journal-title":"Prehosp Emerg Care"},{"issue":"3","key":"503_CR48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1526-4637.2007.00298.x","volume":"8","author":"DR Taylor","year":"2007","unstructured":"Taylor\u00a0DR, Webster\u00a0LR, Chun\u00a0SY et\u00a0al (2007) Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 8(3):281\u2013288","journal-title":"Pain Med"},{"issue":"5","key":"503_CR49","first-page":"131","volume":"24","author":"DR Taylor","year":"2013","unstructured":"Taylor\u00a0DR (2013) Single-dose sublingual spray for breakthrough cancer pain. Clin Pharmacol 24(5):131\u2013141","journal-title":"Clin Pharmacol"},{"key":"503_CR50","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2147\/JPR.S106177","volume":"9","author":"MA Ueberall","year":"2016","unstructured":"Ueberall\u00a0MA, Lorenzl\u00a0S, Lux\u00a0EA et\u00a0al (2016) Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain. J\u00a0Pain Res 9:571\u2013585","journal-title":"J Pain Res"},{"issue":"3","key":"503_CR51","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.drugalcdep.2010.01.001","volume":"108","author":"WM Walwyn","year":"2010","unstructured":"Walwyn\u00a0WM, Miotto\u00a0KA, Evans\u00a0CJ (2010) Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions. Drug Alcohol Depend 108(3):156\u2013165","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"503_CR52","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/cncr.24279","volume":"115","author":"SM Weinstein","year":"2009","unstructured":"Weinstein\u00a0SM, Messina\u00a0J, Xie\u00a0F (2009) Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer 115(11):2571\u20132579","journal-title":"Cancer"},{"issue":"1","key":"503_CR53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00482-013-1292-3","volume":"27","author":"S Wirz","year":"2013","unstructured":"Wirz\u00a0S, Wiese\u00a0CH, Zimmermann\u00a0M et\u00a0al (2013) Schnell freisetzende Fentanylapplikationsformen \u2013 Stellungnahme des Arbeitskreises Tumorschmerz der Deutschen Schmerzgesellschaft. Schmerz 27(1):76\u201380","journal-title":"Schmerz"},{"issue":"6","key":"503_CR54","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00482-016-0168-8","volume":"30","author":"S Wirz","year":"2016","unstructured":"Wirz\u00a0S, Schenk\u00a0M, Kleinmann\u00a0B et\u00a0al (2016) Chronifizierungsmechanismen und Abh\u00e4ngigkeitspotenziale bei Tumorschmerz. Vergleich mit Nichttumorschmerz \u2013 eine\u00a0Literatur\u00fcbersicht. Schmerz 30(6):510\u2013518","journal-title":"Schmerz"},{"issue":"2","key":"503_CR55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.burns.2017.10.012","volume":"44","author":"C Yang","year":"2018","unstructured":"Yang\u00a0C, Xu\u00a0XM, He\u00a0GZ (2018) Efficacy and feasibility of opioids for burn analgesia: An evidence-based qualitative review of randomized controlled trials. Burns 44(2):241\u2013248","journal-title":"Burns"},{"key":"503_CR56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0885-3924(00)00161-5","volume":"20","author":"G Zeppetella","year":"2000","unstructured":"Zeppetella\u00a0G, O\u2019Doherty\u00a0CA, Collins\u00a0S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a\u00a0hospice. J\u00a0Pain Symptom Manage 20:87\u201392","journal-title":"J Pain Symptom Manage"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-020-00503-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-020-00503-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-020-00503-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:28:02Z","timestamp":1632529682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-020-00503-8"}},"subtitle":["Stichprobenartige Fragebogenerhebung bei Kongressteilnehmern und Schmerzmedizinern","A\u00a0random questionnaire survey among congress participants and pain physicians"],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1007\/s00482-020-00503-8","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"14 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Wirz, M.\u00a0Schenk, H.\u00a0Hofbauer, H.-C.\u00a0Wartenberg, M.\u00a0Cascella und K.\u00a0Kieselbach geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. Kriterien, nach denen ein Ethikantrag geboten gewesen w\u00e4re, lagen nicht vor. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}